New paradigms for cancer prevention

被引：11

作者：

DuBois, RN ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Dept Cell Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

来源：

CARCINOGENESIS | 2001年 / 22卷 / 05期

关键词：

D O I：

10.1093/carcin/22.5.691

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：691 / 692

页数：2

共 24 条

[1] EPIDERMAL GROWTH-FACTOR [J].

CARPENTER, G ;

COHEN, S .

ANNUAL REVIEW OF BIOCHEMISTRY, 1979, 48 :193-216

[2]

COHEN S, 1962, J BIOL CHEM, V237, P1555

[3]

DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822

[4] TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS [J].

GIARDIELLO, FM ;

HAMILTON, SR ;

KRUSH, AJ ;

PIANTADOSI, S ;

HYLIND, LM ;

CELANO, P ;

BOOKER, SV ;

ROBINSON, CR ;

OFFERHAUS, GJA .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) :1313-1316

[5] THE ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN COLORECTAL-CANCER PREVENTION [J].

GIARDIELLO, FM ;

OFFERHAUS, GJA ;

DUBOIS, RN .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (7-8) :1071-1076

[6] PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs [J].

He, TC ;

Chan, TA ;

Vogelstein, B ;

Kinzler, KW .

CELL, 1999, 99 (03) :335-345

[7]

Jacoby RF, 2000, CANCER RES, V60, P1864

[8]

Kawamori T, 1998, CANCER RES, V58, P409

[9]

Kelloff GJ, 1996, CANCER EPIDEM BIOMAR, V5, P657

[10] A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucose of patients with osteoarthritis [J].

Laine, L ;

Harper, S ;

Simon, T ;

Bath, R ;

Johanson, J ;

Schwartz, H ;

Stern, S ;

Quan, H ;

Bolognese, J .

GASTROENTEROLOGY, 1999, 117 (04) :776-783

← 1 2 3 →